<DOC>
	<DOCNO>NCT01977820</DOCNO>
	<brief_summary>This Phase 2a multicenter , double-blind , placebo-controlled , randomize , 2-arm pilot trial design assess effect sapropterin cognitive ability young adult Phenylketonuria ( PKU ) 26-week treatment period .</brief_summary>
	<brief_title>Sapropterin Cognitive Abilities Young Adults With Phenylketonuria</brief_title>
	<detailed_description />
	<mesh_term>Phenylketonurias</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Written inform consent give trialrelated activity carry Women men document PKU diagnose least two phenylalanine level equal great 600 micromole per liter ( mcmol/L ) For woman childbearing potential : negative urine pregnancy test require screening willingness use highly effective method contraception require study followup period Aged great equal ( &gt; = ) 18 29 year , inclusive Mean blood phenylalanine level 600 1000 mcmol/L 12 month precede inclusion study . The mean calculate least 3 blood phenylalanine value last 12 month . Screening blood phenylalanine level one value . There least one value date Month 12 6 Screening least one value date Month 6 Screening An intelligence quotient ( IQ ) score great equal 85 , assess maximum 2 year screen ageappropriate Wechsler scale . If IQ test result available , IQ test must perform part Screening use ageappropriate Wechsler scale subject include Subjects willing comply study procedure , include willingness continue current dietary recommendation whole trial duration Subjects tetrahydrobiopterin ( BH4 ) deficiency Previous exposure sapropterin BH4 great 30 day ( exposure sapropterin BH4 less equal 30 day within previous 6 month prior Screening visit ) Subjects , accord Investigator , able comply study procedure computerize neuropsychological test Any significant illness , accord Investigator , might preclude participation study ( include neurological disease , cardiovascular disease , history seizure , predisposition convulsion , renal hepatic insufficiency , active malignancy ) Any significant illness , medication substance abuse , accord Investigator , might affect cognitive function cognitive testing ( example , significant visual motor impairment , history major head trauma , history stroke , alcoholism , drug dependency , psychological disorder require chronic use psychotropic medication anxiolytic , antidepressant , antipsychotic medication , mood stabilizer , hypnotic ) Concomitant forbidden medication describe Kuvan® Summary Product Characteristics , namely , inhibitor dihydrofolate reductase ( example , methotrexate , trimethoprim ) , medication know affect nitric oxide synthesis ( example , glyceryl trinitrate , isosorbide dinitrate , sodium nitroprusside , molsidomin , phosphodiesterase type 5 inhibitor , minoxidil ) , levodopa , may cause increased excitability irritability Known hypersensitivity sapropterin ingredient product 's formulation , approve nonapproved formulation BH4 Subjects undergone cognitive neuropsychological test similar perform part trial follow time limit : task limited practice effect perform last 6 month , task important practice effect ( task involve development strategy ) perform year precede inclusion trial . Whether task fall one category leave Investigator judgment Female subject pregnant lactation period Subjects currently participate another clinical trial participate previous clinical trial within 30 day prior screen Legal incapacity limit legal capacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Phenylketonuria</keyword>
	<keyword>Sapropterin</keyword>
	<keyword>Placebo</keyword>
	<keyword>Cognitive Abilities</keyword>
	<keyword>Kuvan®</keyword>
</DOC>